Chronic Hepatitis c
Conditions
Keywords
HCV, Cirrhotic, non-cirrhotic, sofosdac, sofosbuvir, daclatasvir, fixed-dose combination, FDC, hepatitis C, pangenotypic, genotype
Brief summary
A multicentric, observational, open-design study conducted to evaluate the efficacy and safety of Sofosdac® 400mg/60mg tablets treatment in 100 patients with chronic hepatitis C (HCV)
Detailed description
BEKER laboratories developed the generic drug Sofosdac® 400 mg/60 mg Tablets as fixed dose combination that contains two direct antiviral agents (400 mg Sofosbuvir and 60 mg Daclatasvir) known to be pangenotypic in order to fulfill WHO plan to eradicate HCV by 2030. BEKER conducted an observational clinical trial to evaluate the efficacy and safety of FDC Sofosdac® 400 mg/60 mg treatment in Algerian patients with chronic hepatitis C (HCV).
Interventions
COMBINATION_PRODUCTSofosdac®
Once daily fixed-dose combination of 400 mg Sofosbuvir and 60 mg Daclatasvir
Sponsors
Pharmaceutical Research Unit, Jordan
Beker Laboratories
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Men and women age of 18 years old and older. * HCV chronic Infection, genotype 1 or 2 or 3 or 4 or 5 or 6 * Naive * Bi-therapy failure, Tri-therapy 1st generation Telaprévir and Boceprevir, Sofosbuvir - pegIFN - RBV failure * Evaluation of fibrosis by non-invasive methods (Fibroscan, Fib 4, APRI) performed during the pre-inclusion period (of at least one month) or A Liver biopsy puncture of at least 24 months before the inclusion visit. * Fibrosis according to Metavir score: F0, F1, F2, F3, F4. * Compensated Cirrhosis Child-Pugh A or * Decompensated Cirrhosis (This point is applicable for patients who have cirrhosis)
Exclusion criteria
* Patient under amiodarone * Hepatocellular carcinoma HCC * Haemodialysis * Creatinine Clearance \< 30ml/min * Breastfeeding * Impossibility of using effective masculine or feminine contraception during the study and 6 months after treatment cessation. * Medications triggering conduction disturbances with long QT, 30 days prior to inclusion * QT prolongation \> 450 ms * Personal or familial history of torsade de pointes * Allergies to nucleosi(ti)des analogues. * Advanced cardiopulmonary pathology * Malignant neoplasia * The intake of anticonvulsants: Carbamazepine, eslicarbazepine, fosphenytoin, phenytoin, oxcarbazepine, pentobarbital, phenobarbital, primidone or the antimycobacterial agents: Rifabutin, rifampin
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Detection of RNA HCV 12 weeks after treatment cessation by acceptable quantification assay | 12 weeks after treatment cessation | A quantification assay is performed to all patients to detect RNA HCV in order to determine the proportion of patients who achieve SVR12 (Sustained Viral Response) defined as: RNA HCV \< LLOQ (Lower Limit of Quantification) 12 weeks after treatment cessation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of reported adverse events | During treatment duration defined as: 24 weeks for cirrhotics, and 12 weeks for non-cirrhotic patients | Assessment of observed adverse events / adverse effects and serious adverse events related or not related to Sofosdac® treatment. |
Countries
Algeria
Outcome results
None listed